The Senate Committee on Appropriations June 25 approved the fiscal 2016 Labor, Health and Human Services, and Education Appropriations Bill, which would boost NIH’s budget to $32 billion—an increase of $2 billion above fiscal 2015.
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.
